Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · IEX Real-Time Price · USD
3.11
0.04 (1.30%)
May 18, 2022 9:43 AM EDT - Market open
Market Cap248.03M
Revenue (ttm)28.07M
Net Income (ttm)-60.01M
Shares Out79.75M
EPS (ttm)-0.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume976
Open3.11
Previous Close3.07
Day's Range3.10 - 3.11
52-Week Range2.66 - 11.95
Beta0.08
AnalystsBuy
Price Target9.85 (+216.7%)
Earnings DateMar 24, 2022

About IPHA

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tum...

IndustryBiotechnology
IPO DateOct 17, 2019
CEOMondher Mahjoubi
Employees215
Stock ExchangeNASDAQ
Ticker SymbolIPHA
Full Company Profile

Financial Performance

In 2021, Innate Pharma's revenue was 24.70 million, a decrease of -64.60% compared to the previous year's 69.77 million. Losses were -52.81 million, -17.47% less than in 2020.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 10 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price forecast is 9.85, which is an increase of 216.72% from the latest price.

Price Target
$9.85
(216.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)--Upcoming investor conferences

1 week ago - Business Wire

Innate Pharma Reports First Quarter 2022 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports first quarter 2022 financial results and business update

1 week ago - Business Wire

Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has filed a prospectus supplement with the S...

2 weeks ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tue...

2 weeks ago - Business Wire

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From Astra...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) has now dosed...

2 weeks ago - Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 20, 2022

1 month ago - Business Wire

Innate Pharma Files Its 2021 Universal Registration Document (Document d'enregistrement universel) and 2021 Annual Re...

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2021 universal registration document and 2021 annual report on Form 20-F

1 month ago - Business Wire

Innate Pharma Reports Full Year 2021 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma reports Full Year 2021 financial results and business update

1 month ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2021 financial results

2 months ago - Business Wire

Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma obtains €28.7M in non-dilutive financing in the form of State Guaranteed Loans

4 months ago - Business Wire

Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers

MARSEILLE, France--(BUSINESS WIRE)--First patient dosed in IPH6101/SAR443579 Phase 1/2 clinical trial in various blood cancers

5 months ago - Business Wire

Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low ...

5 months ago - Benzinga

Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recu...

MARSEILLE, France--(BUSINESS WIRE)--Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line r/m head and neck cancer at ESMO IO 2021 congress

5 months ago - Business Wire

Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present monalizumab data at ESMO Immuno-Oncology 2021 Congress

5 months ago - Business Wire

Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

5 months ago - Business Wire

Innate Pharma Third Quarter 2021 Report

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Third Quarter 2021 Report

6 months ago - Business Wire

Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC

6 months ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tue...

6 months ago - Business Wire

Innate Pharma 2022 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar: March 24, 2022: Publicat...

6 months ago - Business Wire

Here's Why Innate Pharma Stock Is Rocketing Higher Today

A clinical trial with an experimental lung cancer drug produced some positive results.

8 months ago - The Motley Fool

What Is Happening With Innate Pharma Stock On Friday?

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Onc...

8 months ago - Benzinga

Monalizumab Data From COAST Trial Presented at ESMO Congress 2021

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented r...

8 months ago - GlobeNewsWire

Innate Pharma Reports First Half 2021 Financial Results and Business Update

MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six month...

8 months ago - GlobeNewsWire

Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update

MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on We...

8 months ago - GlobeNewsWire

Why Innate Pharma Shares Are Rising On Friday?

Innate Pharma SA (NASDAQ:IPHA) stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late...

8 months ago - Benzinga